Recent studies move closer to answering questions about sequential therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer

Affiliations

¹ Department of Pulmonary and Critical Care Medicine, Faculty and Graduate School of Medicine, Mie University, Tsu, Japan.
² Department of Immunology, Faculty and Graduate School of Medicine, Mie University, Tsu, Japan.
³ Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Japan.

Editorial

Tetsu Kobayashi et al. J Thorac Dis. 2017 Sep.

. 2017 Sep;9(9):2847-2851.

doi: 10.21037/jtd.2017.08.114.

¹ Department of Pulmonary and Critical Care Medicine, Faculty and Graduate School of Medicine, Mie University, Tsu, Japan.
² Department of Immunology, Faculty and Graduate School of Medicine, Mie University, Tsu, Japan.
³ Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Japan.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E. Shaw AT, et al. Lancet Oncol. 2017 Jul;18(7):874-886. doi: 10.1016/S1470-2045(17)30339-X. Epub 2017 Jun 9. Lancet Oncol. 2017. PMID: 28602779 Clinical Trial.

1. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1995;267:316-7. 10.1126/science.267.5196.316-b - DOI - PubMed
1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. 10.1038/nature05945 - DOI - PubMed
1. Mano H. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci 2008;99:2349-55. 10.1111/j.1349-7006.2008.00972.x - DOI - PMC - PubMed
1. Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A 2008;105:19893-7. 10.1073/pnas.0805381105 - DOI - PMC - PubMed
1. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010;16:5581-90. 10.1158/1078-0432.CCR-10-0851 - DOI - PMC - PubMed